DDInter1042 DDInter1398
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.
Pasireotide {u} (Compound) resembles {v} (Compound) Terlipressin
Pasireotide {u} (Compound) binds {v} (Gene) SSTR5
Pasireotide {u} (Compound) is included by {v} (Pharmacologic Class) Somatostatin Receptor Agonists
Pasireotide {u} (Compound) causes {v} (Side Effect) Abdominal pain
Pasireotide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Pasireotide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Pasireotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Pasireotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metoprolol
Pasireotide {u} may lead to a major life threatening interaction when taken with {v} Protriptyline
Pasireotide {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Pasireotide (Compound) resembles Terlipressin (Compound)
Pasireotide (Compound) binds SSTR5 (Gene)
Pasireotide (Compound) is included by Somatostatin Receptor Agonists (Pharmacologic Class)
Pasireotide (Compound) causes Abdominal pain (Side Effect)
Pasireotide may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Pasireotide may cause a minor interaction that can limit clinical effects when taken with Doravirine
Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol
Pasireotide may lead to a major life threatening interaction when taken with Protriptyline
Pasireotide may lead to a major life threatening interaction when taken with Fingolimod